Data presented at CROI 2012 explain the reason for the lack of PrEP efficacy in the FEM-PrEP trial.
Deciphering the contradictory findings of recent clinical trials of pre-exposure prophylaxis (PrEP) was a major focus of CROI 2012. Since July 2010, several large randomized trials have shown that using topical or oral antiretrovirals reduces the likelihood of HIV acquisition in women, heterosexual couples, and men who have sex with men, with efficacy estimates ranging from 39% to 75%. However, no risk reduction was observed in African women who were prescribed daily oral tenofovir/FTC (Truvada) in the FEM-PrEP trial — or in those who were prescribed daily oral tenofovir or daily vaginal tenofovir gel as part of the VOICE trial.
No data are available yet to explain the VOICE trial outcome, since the tenofovir/FTC arm is continuing and result…
Author
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes